source
- Agios halts development of sickle cell drug tebapivat after mid-stage trial failureAgios announced it will stop developing tebapivat for sickle cell disease after a mid-stage trial did not meet expectations. The drug, a next-generation pyruvate kinase activator related to the ap…
- FDA issues warning letters for CGMP breaches and inadequate trial consent, EU releases AI transparency guidelinesThe U.S. Food and Drug Administration sent warning letters to several drug manufacturers for not meeting current good manufacturing practice requirements. One firm was also cited for failing to pr…